GSK plc Announces Blenrep Approval in China

GSK plc announced that the National Medical Products Administration (NMPA) of China has approved Blenrep (belantamab mafodotin) in combination with bortezomib and dexamethasone (BVd) for the treatment of adults with relapsed or refractory multiple myeloma who have received at least one prior line of therapy. This approval, following priority review and Breakthrough Therapy Designation, is based on the DREAMM-7 phase III trial data. The BVd combination demonstrated a 42% reduction in the risk of death and nearly tripled median progression-free survival compared to a daratumumab-based triplet. Blenrep is the only anti-BCMA therapy approved in China for 2L+ multiple myeloma, offering a new mechanism of action and convenient outpatient administration. Multiple myeloma is a significant global health challenge, with increasing incidence and mortality. Blenrep, as an antibody-drug conjugate, provides a differentiated treatment option with manageable side effects, suitable for various patient types and treatment settings.